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Background: Introducing comprehensive smoke-free policies to public places is expected to reduce
health costs. This includes prevented health damages by avoiding environmental tobacco smoke (ETS)
exposure as well as indirect health benefits from reduced tobacco consumption. Methods: The aim of
this study was to estimate direct health costs of ETS exposure in public places and indirect health
benefits from reduced tobacco consumption. We calculated attributable hospital days and years of
life lost (YLL), based on the observed passive smoking and disease rates in Switzerland. The
exposure–response associations of all relevant health outcomes were derived by meta-analysis from
prospective cohort studies in order to calculate the direct health costs. To assess the indirect health
benefits, a meta-analysis of smoking ban studies on hospital admissions for acute myocardial infarction
was conducted. Results: ETS exposure in public places in Switzerland causes 32 000 preventable hospital
days (95% CI: 10 000–61 000), 3000 YLL (95% CI: 1000–5000), corresponding to health costs of 330 Mio
CHF. The number of hospital days for ischaemic heart disease attributable to passive smoking is much
larger if derived from smoking ban studies (41 000) than from prospective cohort studies (3200),
resulting in additional health costs of 89 Mio CHF, which are attributed to the indirect health
benefits of a smoking ban introduction. Conclusion: The example of smoking ban studies on
ischaemic heart disease hospitalization rates suggests that total health costs that can be prevented
with smoking bans are considerably larger than the costs arising from the direct health impact of ETS
exposure in public places.
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Introduction
During the past years, comprehensive smoke-free policiesfor public places have been introduced in various
countries (France, Ireland, Italy, the UK, parts of the USA
and Canada). Other countries (Switzerland, Germany or
Japan) do not have comprehensive smoking bans.1–3 The
introduction of smoking bans for public places resulted
in a reduction of environmental tobacco smoke (ETS)
exposure of hospitality workers4,5as well as of the general
population.6,7
Beside reduction of ETS exposure, studies demonstrated that
the introduction of smoking bans in public places and
workplaces were followed by a reduction of the tobacco con-
sumption in many countries, such as Italy,8 the USA, Australia,
Canada and Germany.9
After the introduction of smoking bans, regional studies in
Europe and North America found reductions of hospital
admissions due to myocardial infarctions.10–12
Such smoking ban studies have the advantage of not only
considering the direct health effects from ETS exposure, but
also the indirect health effects that accompany the introduction
of a smoking ban such as the reduction of tobacco consump-
tion of smokers. These indirect benefits are also relevant for
policy decision makers in order to estimate the total health
benefits associated with the introduction of a comprehensive
smoke-free policy. However, these indirect benefits are not
captured by conventional health impact assessments (HIA)
that quantify only the direct health consequences of passive
smoking based on exposure–response associations between
health outcomes and ETS exposure derived from epidemio-
logical studies.
To our knowledge, smoking ban studies have not been
used for HIA, so far, to estimate direct and indirect
preventable health costs when introducing a smoking
ban. Therefore, our aim is to estimate the direct health
costs related to ETS exposure in public places in
Switzerland from available epidemiological research and
additionally by evaluating indirect preventable health costs
by considering the results of recently published smoking
ban studies.
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Methods
Selection of the health effects
All health outcomes with sufficient or suggestive causal rela-
tionship to ETS exposure according to the Surgeon General
report were considered relevant for this HIA a priori.13 From
these, we did not consider health effects for which health costs
cannot be determined (e.g. annoyance). In addition, we only
included clearly delimitable health effects in order to avoid
double counts. Breast cancer was excluded because we found
no increased risk in a meta-analysis of prospective cohort
studies. Finally, we were left with the following outcomes:
ischaemic heart disease, stroke, lung cancer, nasal sinus
cancer, chronic obstructive pulmonary disease (COPD),
asthma, hospital admissions due to respiratory diseases and
preterm delivery.
Derivation of the exposure–response associations
The exposure–response associations between ETS exposure
and the selected health outcomes were derived from
epidemiologic literature. For lung cancer and ischaemic heart
disease, we carried out a systematic literature review including
a meta-analysis. For all other health effects, we derived the
exposure–response association by meta-analysis from all
studies mentioned in the Surgeon General report13 or we
used newer peer reviewed meta-analyses in the case of
stroke.14,15
We only considered prospective cohort studies as they are
not prone to recall bias and generally assumed to be most
reliable. In addition, we considered smoking ban studies in
order to evaluate indirect health benefits of smoking ban intro-
duction on ischaemic heart disease hospitalization rates.
In our systematic review of lung cancer and ischaemic heart
disease studies, we searched EMBASE and MEDLINE to
identify relevant studies published prior to 2009. From each
publication, data were independently extracted by two
experienced epidemiologists using structured data extraction
sheets. To be considered for inclusion, the relevant studies
had to be in English or German and had to be carried out in
Europe, North America, Japan, South Korea, Australia and
New Zealand, since these regions represent most adequately
the Swiss situation in terms of exposure. Relevant studies
had to quantify the ETS exposure as well as the exposure–
response associations including measure of precision (e.g.
confidence interval). In addition, selected studies had to be
peer reviewed. If several publications were available from the
same cohort, we only considered the most comprehensive data
analysis. We excluded studies that were solely done in patients.
We calculated separate effect estimates for YLL and hospital
days’ calculation based on incidence (morbidity) and/or
mortality studies. Depending on the heterogeneity between
the studies, we used random or fixed effect models for our
meta-analyses.
Determination of the ETS exposure
In the framework of our research question, we only considered
ETS exposure in public places (restaurants, cafes, bars, events,
workplaces, schools and universities). We took into account
data on ETS exposure for the year 2006 when no smoke-free
policies had been implemented on a compulsory base in
Switzerland. Public transport had introduced a smoking ban
in trains at the end of 2005.
Data on the ETS exposure of the Swiss population were
obtained from the Swiss tobacco monitoring, which is
carried out on behalf of the Federal Office of Public Health
every 3 months, since 2001.16,17 It is a representative survey
among 2500 persons in Switzerland aged between 14 and
65 years. We used the data from the fourth quarter of 2006
to calculate the cumulative exposure time per week for all type
of public places including work places. For the age group
>65 years, we used the data from the age group 55–65 years
but excluded ETS exposure at workplace.
For our HIA, we assumed that ETS exposure of >7 h a week
at public places is approximately the same as living with a
smoker. This is the typical exposure status of exposed study
participants in prospective cohort studies.
Observed health frequencies
For all morbidity outcomes except preterm delivery, we
calculated the attributable hospital days as this is particularly
relevant for the cost estimates. Age-specific numbers of
hospital days were obtained for each relevant diagnosis using
the number of stationary cases and the average length of stay of
the year 2006 from the medical statistics of Swiss hospitals.18
Mortality data for the YLL calculation were derived from the
official Swiss mortality statistics of the year 2006.19
Calculation of attributable cases
For our calculation, we used a hypothetical scenario with a
smoking ban in force, i.e. no ETS exposure at public places.
Thus the expected number of hospital days for the hypothetical
scenario (Nh) is obtained from the observed number of
hospital days (No) the following way:
Nh ¼ No
RRexp
ð1Þ
where,
RRexp ¼ Pnot exposed þ ðPexposed  RRÞ ð2Þ
RR is the exposure response association of ETS exposure, and
P is the proportion of the population exposed or not exposed,
respectively. Smoking ban studies are based on the whole
population, and thus do not require knowledge about the
exposure distribution of the target population. Thus, the
number of expected hospital days after the introduction of a
smoking ban is obtained from the pooled risk estimate of the
smoking ban studies (RRban) the following way:
Nh ¼ No  RRban ð3Þ
To obtain the hospital days attributable to passive smoking, we
subtracted the expected number of hospital days of the hypo-
thetical scenario (Nh) from the observed number of hospital
days. Since ETS exposure and the observed health frequencies
are age dependent, we calculated all attributable cases for three
different age groups separately (15–39, 40–69, 70 years) and
added them up.
Calculation of the YLL
YLL were calculated using the method described in Miller and
Hurley20,21 for fatal health outcomes (ischaemic heart diseases,
stroke, lung cancer, nasal sinus cancer and COPD). We
calculated life tables using the observed hazard rates for the
reference scenario and the modified hazard rates without ETS
exposure for the hypothetical scenario without ETS exposure
at public places. For the reference scenario, we applied the
observed age-specific mortality rates to project and estimate
the age-specific number of deaths for every fatal health
outcome in each year until the year 2100 and computed the
number of life years using a cohort life table. The same
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procedure was applied with modified survival functions
reflecting the absence of ETS exposure. Calculations were
done for 10-year age categories reflecting the exposure
situation and relative risk of the corresponding age groups.
We also took into account a time lag between ETS exposure
and health impact (latency of 13 years for carcinogenic
diseases, 1.5 years for cardiovascular disease22 and 2 years for
COPD).23
Determination of the health costs
The health costs consist of medical treatment costs (hospital
days), costs due to net loss of production, the costs of reoccu-
pation due to death of an employee and the immaterial costs
that comprise the costs for pain and suffering. The cost rates
and their sources are given in table A1.
Medical treatment costs were determined for each health
outcome separately from the All Patient Diagnosis Related
Groups (APDRG) Suisse.24 The data of the APDRG Suisse
are based on a sample of 290 000 hospitalizations, collected
between 2001 and 2003.
The costs due to net loss of production arise from work
absence of adults (between 17 and 65 years). Work absence
was assumed to be doubled as long as the stay at the hospital,
as it was done in other impact assessments.25–27 Unlike costs
per case of illness, costs per day due to net loss of production
are independent of the disease and the same costs per hospital
day were used for all health outcomes. Net production loss
of a YLL corresponds to a full year of work absence, which is
CHF 49 000.28
The immaterial costs were estimated by the willingness
to pay method. Immaterial costs of a hospital day were
determined from a Californian survey that is based on a
sample of 394 persons of a median age of 67 years.29 The
cost rate, published in this study, lies between those of two
European studies.27,30 In this study, cost rates for hospital days
were not different according to diagnosis. The cost rate for the
immaterial costs of an YLL corresponds to the value of a life
year lost (VLYL), which is independent from the age structure
of the concerned people. Since there are no estimations for
VLYL, the VLYL are derived from the discounted sum of the
YLL. Thereby a discount rate of 2% was used. This procedure
was also applied in several projects of the European Union
(UNITE, HEATCO, IMPACT)31–33 and in other Swiss health
impact assessment.26
For preterm delivery, the additional costs compared to a
normal birth are considered. These costs are also provided
by the APDRG Suisse.24
In order to estimate the health costs that can be prevented
by the introduction of a smoking ban, estimated cost rates for
every health outcome were multiplied with the attributable
cases and YLL. We also took into account the costs of ETS
exposure in 2006 which arose after 2006. Thereby, the YLL
were multiplied with a discount rate of 1%, considering a
discount rate of 2% but corrected by the real wage growth.
Results
In 2006, 21% of the Swiss population were exposed to ETS in
public places for >7 h a week. Exposure was highest in 20- to
24-year-old people (53%) decreasing with increasing age
(Supplementary table S1).
In our systematic review, the pooled effect estimate of ETS
exposure for ischaemic heart disease morbidity was 1.17 (95%
CI: 1.12–1.23) based on 10 prospective studies on ischaemic
heart disease morbidity and mortality (Supplementary
figure S1), 1.17 (95% CI: 1.12–1.22) for ischaemic heart
disease mortality based on 8 prospective cohort studies
(Supplementary figure S2), 1.63 (95% CI: 1.29–2.04) for lung
cancer morbidity based on four prospective studies
(Supplementary figure S3) and 1.36 (95% CI: 1.17–1.58)
for lung cancer mortality based on five prospective studies
(Supplementary figure S4). Table A2 gives an overview on all
effect estimates obtained from meta-analyses.
Combining relative risks from prospective cohort studies
with observed hospital days (table A2) and the number of
exposed individuals yields the direct health consequences of
ETS exposure. In total, exposure to ETS in public places
in Switzerland results in approximately 32 000 (95% CI:
10 000–61 000) additional hospital days and 179 (95% CI:
0–682) preterm deliveries (table A3). Life table calculations
yielded about 3000 YLL (95% CI: 1500–5000) due to ETS
exposure in public places, mainly owing to lung cancer
[1500 (95% CI: 700–2300)] and ischaemic heart disease
[1000 (95% CI: (700–1300)].
Overall, the direct health consequences from ETS exposure
in public places causes health costs of 330 Mio CHF thereof
129 Mio CHF are attributable to lung cancer and 93 Mio CHF
are attributable to ischaemic heart disease (table A3).
Indirect health benefits from smoking bans are evaluated
with smoking ban studies. The introduction of a smoking
ban reduced hospital admissions for ischaemic heart disease
by 0.84 (95% CI: 0.80–0.88) (Supplementary figure S5).
Estimating hospital admissions for ischaemic heart disease
from smoking ban studies instead of prospective cohort
studies results in 13 times higher number of estimated attrib-
utable cases, because the relative risk reduction is relevant to
the whole population and not only to the exposed proportion
(table A4). Hence, health costs due to ischaemic heart disease
morbidity are 89 Mio CHF in addition to the conventional
HIA of 8 Mio CHF based on prospective cohort studies.
Using the effect estimate for hospital admissions for
ischaemic heart disease derived from smoking ban studies
instead of the one from prospective cohort studies to
estimate the number of YLL due to ischaemic heart disease
mortality would result in a 16 times higher estimate
(YLL = 15 000; 95% CI: 11 000–20 000), and hence health
costs due to ischaemic heart disease would almost amount to
1.5 billion CHF (table A4).
Discussion
In 2006, 21% of the Swiss population were exposed to ETS for at
least 7 h/week. This caused 32 000 hospital days (95% CI:
10 000–61 000), 3000 YLL (95% CI: 1500–5000) and thus
direct health consequences of ETS exposure correspond to 330
Mio CHF in health costs. Smoking ban studies on hospital
admissions due to ischaemic heart diseases suggest that an
additional 38 000 hospital days corresponding to 89 Mio CHF
can be avoided if a comprehensive smoking ban is introduced.
Our estimates of the direct health consequences of passive
smoking tended to be somewhat lower than in similar studies
from Spain and the UK. For instance, we estimated that 1.7%
of all ischaemic heart disease deaths among people in working
age (aged between 15 and 69 years) in Switzerland were due to
ETS exposure (table A4).
In the UK, workplace-related ETS exposure was estimated to
be responsible for 2.2% of all ischaemic heart disease deaths;34
and in Spain, workplace-related ETS exposure was estimated to
cause between 1.1% and 3.9% of all ischaemic heart disease
deaths.35
For lung cancer, the attributable fractions were 3.4% in
Switzerland, 2.6% in the UK and 2.1–12.3% in Spain. The
main reason for our rather low estimates is the lower ETS
exposure in our study. Whether this is a true difference
between the three countries or whether exposure differences
are due to different methods that were used to determine the
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proportion of the exposed population cannot be answered with
the available information.
To our knowledge, this is the first HIA that takes into
account smoking ban studies to estimate preventable health
costs when introducing a smoking ban to public places.
Interestingly, compared with the conventional HIA
approach that quantifies the direct health consequences of
passive smoking based on prospective cohort studies, the con-
sideration of smoking ban studies resulted in a much higher
estimated number of preventable hospital days due to
ischaemic heart disease. At a first glance, this substantial
difference seems to be implausible because the relative risks
of these studies are similar. A relative risk of 0.84 for
smoking ban introduction corresponds quite well to the
converse of the relative risk of the prospective cohort studies
(1.18), which is the pooled effect estimate for persons being
exposed to ETS at home from their partner. However, smoking
ban studies are based on the whole population whereas pro-
spective cohort studies express the risk only for a relatively
small proportion of exposed persons. As a consequence,
similar relative risks mean totally different number of attrib-
utable cases. Recently, Lightwood and Glantz36 demonstrated
that the results of the smoking ban studies are compatible with
the prospective cohort studies if one assumes that the intro-
duction of comprehensive smoke-free policies reduces tobacco
consumption and results in quitting smokers as observed in
various countries.8,9 It was demonstrated among Japanese
women and men that 1 year after having quit smoking, the
relative risk of cardiovascular disease was reduced by 19%.37
The indirect health benefit of a smoking ban on smokers is
supported by 2 smoking ban studies with separate analyses for
smokers and non-smokers, which found similar relative
reduction rates in hospital admissions for acute myocardial
infarction for smokers and non-smokers.7,38 Hence, the intro-
duction of smoking bans in public places could also help to
reduce health costs due to active smoking that are assumed to
be much higher than the costs resulting from the direct health
consequences of ETS exposure.
Unfortunately, smoking ban studies are not eligible for
investigating long-term effects such as lung cancer and thus
the studies available to date have only addressed acute effects
on ischaemic heart disease hospitalization rates. Thus, indirect
health benefits of smoking ban introduction can only be
quantified for this outcome. If one applied the effect estimate
for hospitalization rates also on ischaemic heart disease
mortality to estimate the YLL, the fraction of ischaemic heart
disease mortality attributable to ETS exposure would be much
higher (16.5%) and the corresponding health cost estimates
would exceed 1 billion CHF (table A4). This demonstrates
that the indirect health benefits of a smoking ban introduction
may be considerably higher than the direct health benefits from
avoiding ETS exposure in public places.
Nevertheless, the extent of the direct and the indirect health
benefits depend on the type of smoke-free policy. The more
comprehensive a smoking ban is implemented, the more
health benefits are expected. Smoking ban studies were
mainly conducted in countries with comprehensive
smoke-free policies such as Scotland, Ireland and Italy. In
Switzerland, a few regions have introduced smoke-free
policies since 2006. But most of these regulations allow
exceptions like separate smoking rooms in restaurants.
Similarly, the national law on the protection from ETS
exposure, which will come into force on 1 May 2010, allows
several exceptions as smoking will be still allowed in restaur-
ants with a total square footage of up to 80 m2 and customers
are also served in smoking lounges. A measurement campaign
in Swiss hospitality venues demonstrated that fine particulate
matter concentrations (PM2.5) in non-smoking rooms of res-
taurants that allow smoking in a separate room are more than
twice as high as in venues were smoking is not allowed at all.
This reduces the direct health benefits from a smoking ban.39
Possibly, smoke-free policies with many exceptions such as the
national law in Switzerland from the 1st May 2010 have little
impact on tobacco consumption and the quitting rates among
smokers. This also reduces indirect health benefits of smoking
ban introduction. Actually, this hypothesis is in line with the
result of a recent small smoking ban study from one Swiss
region where declined acute myocardial infarction hospitaliza-
tion rates were observed in non-smokers but not in smokers.12
In conclusion, our HIA based on smoking ban studies
suggests that the prevented health costs from introducing a
smoking ban are considerably larger than what would be
expected from the ETS exposure alone, because indirect health
benefits in smokers have been demonstrated as well. The extent
of these indirect effects, however, depends on the type of smoke-
free regulation. The more widespread smoking is removed from
the public places, the more health benefits can be expected.
Supplementary Data
Supplementary data are available at EURPUB online.
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Key points
 This is the first HIA which takes into account smoking
ban studies to estimate preventable health costs when
introducing a smoking ban to public places.
 Our study captures not only the direct effects of ETS
exposure on myocardial infarction, but also indirect
health benefits due to the introduction of smoking
bans in public places such as the reduction of
tobacco consumption in smokers.
 This study suggests that these indirect effects are even
more public health relevant than the direct exposure
effects.
 The extent of these indirect effects depends on the type
of smoke-free regulation. The more widespread
smoking is removed from public places, the more
health benefits can be expected.
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Appendix 1
Table A2 Observed hospital days, deaths and effect estimates, derived from meta-analyses of epidemiologic
studies
Health effect Observed
frequencies
Effect
estimate
(95% CI)
Cardiovascular diseases
Hospital days due to ischaemic heart disease (smoking ban introduction) 248 205 0.84 (0.80–0.88)
Hospital days due to ischaemic heart disease
(prospective studies on ischaemic heart disease mortality and morbidity)
1.17 (1.12–1.23)
Death from ischaemic heart disease 9190 1.17 (1.12–1.22)
Hospital days due to stroke 208958 1.14 (0.99–1.31)
Death from stroke 3320 1.14 (0.99–1.31)
Carcinogenic diseases
Hospital days due to lung cancer 75 318 1.63 (1.29–2.04)
Death from lung cancer 2942 1.36 (1.17–1.58)
Hospital days due to breast cancer 63 951 1.01 (0.92–1.11)
Death from breast cancer (women) 1330 1.01 (0.92–1.11)
Hospital days due to nasal sinus cancer 472 2.06 (1.18–3.61)
Death from nasal sinus cancer (women) 8 2.06 (1.18–3.61)
Respiratory diseases
Hospital days due to COPD 97926 1.40 (1.10–1.77)
Death from COPD 1584 1.40 (1.10–1.77)
Hospital days due to asthma 35271 1.67 (0.88–3.17)
Hospital days due to other respiratory disease 338 515 1.56 (1.14–2.12)
Other diseases
Number of preterm deliveries 6603 1.13 (0.83–1.53)
Table A1 Cost rates in CHF
Medical
treatment costs
Net production
lossa
Immaterial
costs
Total
Costs per hospital day
Ischaemic heart disease 1453b 269d 814c 2535
Stroke 863b 269d 814c 1945
Lung cancer 911b 269d 814c 1993
Nasal sinus cancer 1386b 269d 814c 2468
Asthma 759b 269d 814c 1841
COPD 739b 269d 814c 1822
Other respiratory disease 1066b 269d 814c 2149
Additional costs due to preterm delivery 24 235b n.a. 24 235
Costs per YLL
All health end points 49 008d 93 567e 142 575
Reoccupation costs per death of an employee 28009f
a: Net production loss is only calculated for employees, whereas all other costs are always taken into account. The
cost rate per hospital day has been doubled to take into account the convalescence at home
b: Based on own evaluation of the APDRG Suisse (all patient diagnosis related groups)24
c: Based on Chestnut et al., 200629
d: Based on official statistics from Switzerland (Swiss Statistics)28
e: Based on E1.5 millions (1998 market prices) from the EU-project UNITE33
f: Based on official salary data (Swiss Statistics) and reoccupation costs of 50% of a yearly salary40,41
n.a. = not available.
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